Collaboration extension through 2029 accelerates access to MRD technology across four major cancer types Colorectal cancer affects over 150,000 new patients in the U.S. annually, with many patients ...

We recently compiled a list of the Top 12 AI Stock News and Ratings Dominating Wall Street. In this article, we are going to take a look at where Tempus AI, Inc (NASDAQ:TEM) stands against the other ...

CHICAGO--(BUSINESS WIRE)-- Northwestern Medicine and Tempus AI, Inc. (TEM) are collaborating to expand access to genomic testing for Northwestern Medicine cancer patients. The goal is to provide ...

Tempus AI, Inc (NASDAQ:TEM) is a healthcare technology company that provides AI-enabled precision medicine solutions. On December 16, the company announced that it has expanded its relationship with ...

FREMONT, Calif.--(BUSINESS WIRE)--Personalis, Inc. (Nasdaq: PSNL), a leader in MRD testing, announced findings presented this week at the European Society of Medical Oncology Congress (ESMO) Congress ...

The NeXT Personal test uses whole-genome sequencing and noise-suppression technology to track up to 1,800 mutations in a patient's tumor.

Tempus AI TEM is leaning into a dual-engine model: a fast-growing Genomics franchise and a scaling data business powered by an expanding AI toolkit. The third quarter of 2025 marked a turn to non-GAAP ...